Leadership - Starpharma

Leadership

	Jackie Fairley, B.Sc, B.VSc (Hons), MBA, GAICD, FTSE Chief Executive Officer Dr Jackie Fairley has more than 30 years of operational experience in the pharmaceutical and biotechnology industries working in senior management roles with companies including CSL and Faulding/Hospira (now part of Pfizer). She was appointed Chief Executive Officer of Starpharma Holdings Ltd in July 2006. She holds first class honours degrees in Science (pharmacology and pathology) and Veterinary Science from the University of Melbourne and was a practicing veterinary surgeon prior to joining CSL. Whilst at CSL she obtained an MBA from the Melbourne Business School where she was the recipient of the prestigious Clemenger Medal. Jackie is a non-executive director of the listed investment company Mirrabooka Investments Limited, is a member of the Invest Victoria Advisory Board (IVAB) and Carnegie Venture Capital’s investment Committee. She has previously served on the Melbourne Business School Board, the Australian Federal Government’s Commonwealth Science Council and Pharmaceutical Industry Working Group and the Australian Federal Ministerial Biotechnology Advisory Council.
	Tony Eglezos, B.Sc (Hons), PhD, MBA Vice President, Business Development Dr Eglezos has worked for more than 20 years in the pharmaceutical industry in Australia, the US and Europe for companies including CSL, Amgen, Abbott Labs and Abbott Australasia. Most recently he was Director Commercial Operations, Pharmaceuticals, and In-Licensing at bioCSL and, prior to that, Senior Director Business Development and Licensing at CSL. During his 7 years in business development with CSL, Tony’s responsibilities included acquisitions and due-diligence, commercialisation of in-licensed pharmaceutical products and out-licensing of IP for partnered development for the global R&D group. Tony has a PhD in Immunology from the University of Melbourne and an MBA from the University of Technology Sydney.
	Jeremy Paull, B.Sc (Hons), PhD Vice President, Development and Regulatory Affairs Dr Jeremy Paull has more than 20 years’ experience in pharmaceutical and medtech product development, regulatory affairs, and commercialisation. Jeremy has managed all aspects of multiple development and commercialisation projects for products in areas including HIV/STIs, infectious diseases, women’s health, dermatology, and oncology, and has achieved market approval and commercialisation of medical device and combination products in global markets. Jeremy has also advanced pharmaceutical products through late stage, global phase 3 clinical trials, and led engagement with global regulatory agencies (FDA, EMA, TGA, MHRA, PMDA). Jeremy leads a team of senior technical managers and was Principal Investigator for two concurrent US NIH-funded, multi-year, multi-million dollar research and product commercialisation programs involving collaborations with world-renowned, local and international academic institutions and commercial partners. He is a current member of AusBiotech’s AusMedtech Regulatory Affairs Expert Panel and past member of the AusMedtech Victoria Committee. Jeremy has been a member of the executive leadership team of Starpharma since 2003 and has completed executive leadership training at Kellogg School of Management at Northwestern University, Melbourne Business School, and Australian Graduate School of Management at UNSW. He joined Starpharma in 2001 from medtech company, Norwood Abbey, and has a PhD in pharmacology from Monash University.
	Justin Cahill, *BBus, MPA, CPA* Chief Financial Officer & Company Secretary Mr Cahill has more than 15 years’ experience in corporate finance and leadership roles in the biopharmaceutical, food, and agricultural sectors for both ASX-listed companies and in private companies. Prior to joining Starpharma, Mr Cahill was Chief Financial Officer (CFO) of Paradigm Biopharmaceuticals; and CFO at Diver Foods; and has held senior roles at ASX-listed company Costa Group and at CSL, including 5 years as Divisional CFO of CSL Plasma based in the United States. In these roles, Mr Cahill was responsible for financial performance, financial planning and reporting, compliance, and capital control. Mr Cahill is a Certified Practicing Accountant (CPA) and holds a Master of Professional Accounting and a Bachelor of Business from Swinburne University.